Sort
10,766 grants matching “checkpoint inhibitor”
Development of Mouse and Humanized Models to Study Sex Disparities in Tumor Progression and Treatment of NSCLC
$172,376Joseph William Landry · Virginia Commonwealth University · R21 · FY2024 · CA
Programmable biohybrid system for cancer therapy
$172,044Jaeseung Hahn · Columbia University Health Sciences · K99 · FY2025 · CA
Programmable biohybrid system for cancer therapy
$172,044Jaeseung Hahn · Columbia University Health Sciences · K99 · FY2024 · CA
Target metabolic vulnerabilities of MDSCs to enhance cancer immunotherapy
$171,932Bin Zheng · Massachusetts General Hospital · R21 · FY2020 · CA
Adaptive signaling exposes a therapeutic vulnerability in NRAS melanomas
$171,825Michael J Weber · University Of Virginia · R21 · FY2015 · CA
CONTROL OF INITIATION OF DNA REPLICATION IN LUNG CANCER
$171,775Mount Sinai School Of Medicine Of Nyu · R01 · FY2005 · CA
An immunocompetent platform for the characterization and discovery of novel therapeutics for hepatocellular carcinoma
$171,720Alexander Rialdi · Icahn School Of Medicine At Mount Sinai · K99 · FY2023 · CA
Molecular Regulation of B cells and T cells in Human SLE
$171,686Ignacio E. Sanz · Emory University · U19 · FY2021 · AI
IMMUNOBIOLOGY OF MALIGNANT GLIOMA
$171,651Gavin Peter Dunn · Washington University · K08 · FY2016 · NS
(PQ8) Biomarker identification by mass cytometry in peripheral blood of patients with renal cell carcinoma undergoing immune checkpoint therapy
$171,499Wendy Jane Fantl · Stanford University · R21 · FY2020 · CA
A Novel Microbiome-Based Immune-Modulator that Potentiates Cancer Checkpoint Therapy
$171,480Gary Fanger · Rise Therapeutics, Llc · R44 · FY2024 · CA
An immunocompetent platform for the characterization and discovery of novel therapeutics for hepatocellular carcinoma
$171,480Alexander Rialdi · Icahn School Of Medicine At Mount Sinai · K99 · FY2022 · CA
Development Therapeutics Branch Clinical Trials
$171,349Yves Pommier · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
Novel NEK2 signaling pathways in myeloma progression
$171,306Fenghuang Zhan · Univ Of Arkansas For Med Scis · R01 · FY2023 · CA
NEUROPATHOLOGY/TISSUE BANK CORE
$171,274Claudia Katharina Petritsch · Stanford University · U54 · FY2021 · CA
UNDERSTANDING THE IMMUNE BIOLOGY OF CHECKPOINT INHIBITORS TO DEVELOP NEW STRATEGIES FOR THERAPY
$171,083The Univeristy Of Texas M.D. Anderson Cancer Center · · FY2016 · Department of the Army
Molecular Programming of CD8+ T Cell Accumulation and Activity in Tumors
$171,035John Justin Milner · Univ Of North Carolina Chapel Hill · R00 · FY2021 · CA
Precision Medicine by Targeting Cell Adhesion in Melanoma
$170,856Alexander Meves · Mayo Clinic Rochester · K08 · FY2019 · CA
Precision Medicine by Targeting Cell Adhesion in Melanoma
$170,856Alexander Meves · Mayo Clinic Rochester · K08 · FY2020 · CA
Precision Medicine by Targeting Cell Adhesion in Melanoma
$170,856Alexander Meves · Mayo Clinic Rochester · K08 · FY2021 · CA
Dissecting mechanisms of immunotherapy resistance in melanoma patients
$170,856Benjamin Izar · Columbia University Health Sciences · K08 · FY2020 · CA
Project 1: Elucidating the role of AAA ATPase TRIP13 in prostate cancer
$170,775Sooryanarayana Varambally · University Of Alabama At Birmingham · U54 · FY2021 · CA
Characterization of altered immunity in patients with inflammatory arthritis induced by immune checkpoint inhibitor therapy
$170,640Sang Taek Kim · University Of Tx Md Anderson Can Ctr · K08 · FY2022 · AR
Characterization of altered immunity in patients with inflammatory arthritis induced by immune checkpoint inhibitor therapy
$170,640Sang Taek Kim · University Of Tx Md Anderson Can Ctr · K08 · FY2021 · AR
MOLECULAR PHARM. AND BIOCHEM. OF NOVEL DUAL SPECIIFICITY PHOSPHATASE INHIBITORS
$170,406John S Lazo · University Of Pittsburgh At Pittsburgh · P01 · FY2006 · CA